QIAGEN BEVERLY, LLC – Trademark Portfolio
Entity Type: 16
QIAGEN BEVERLY, LLC holds 16 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 15 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 3 Nice Classification classes. Currently, 16 trademarks are registered. Notable registered marks include WARMX, FASTMIX, QSCRIPT, REPLIQA, and VERASEQ. The owner is based in BEVERLY, MA.
SUITE 407J
100 CUMMINGS CENTER
BEVERLY, MA 01915
Showing of trademarks Trademarks
Trademark Classifications
QIAGEN BEVERLY, LLC's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Frequently Asked Questions
How many trademarks does QIAGEN BEVERLY, LLC have?
QIAGEN BEVERLY, LLC has 16 U.S. trademarks filed with the USPTO. Of these, 16 registered.
What trademark classes does QIAGEN BEVERLY, LLC file in?
QIAGEN BEVERLY, LLC files trademarks across 3 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.
What are QIAGEN BEVERLY, LLC's most well-known trademarks?
QIAGEN BEVERLY, LLC's registered trademark portfolio includes well-known marks such as WARMX, FASTMIX, QSCRIPT, REPLIQA, and VERASEQ. These are among 16 currently registered trademarks in the portfolio.
What is QIAGEN BEVERLY, LLC's trademark registration success rate?
QIAGEN BEVERLY, LLC has a 100% trademark registration rate, with 16 out of 16 resolved applications resulting in successful registration. Currently, 0 applications are pending review.